BGI SENTIS™ Hereditary Breast and Ovarian Cancer Panel
BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.
BGI’s Hereditary Breast and Ovarian (HBOC) panel provides health providers with information on 21 genes associated with Hereditary Breast and Ovarian Cancer (HBOC) based on recent scientific and clinical literature. BGI detects different alterations including germline SNV, Indels and CNVs.
Panels and Genes
Sentis BRCA (2 genes) panel
Sentis Hereditary Breast and Ovarian (21 genes) panel
BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1,NBN, MRE11A,MSH2, MSH6, MUTYH, PMS1,PMS2, RAD50, RAD51C
Why Choose the BGI SENTIS™ – Hereditary Breast and Ovarian Cancer Panel?
- Comprehensive – whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements
- Robust – clinically important (pathogenic or likely pathogenic) variants are verified by Sanger Sequencing while large gene rearrangements are verified by qPCR
- Convenient – test from blood or saliva; DNA is also accepted
- Professional – state-of-the-art variant database ensures up-to-date analysis and interpretation.
Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.